Assessing the risk of recurrent venous thromboembolism – A practical approach

Vascular Health and Risk Management

Volumn 11, Issue , 2015, Pages 451-459

  Fahrni, Jennifer ^a   Husmann, Marc ^b   Gretener, Silvia B ^c   Keo, Hong H ^a  

^a Kantonsspital Frauenfeld   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Clinic for Angiology Oberaargau   (Switzerland)

Author keywords

Hemorrhage; Hrombosis; Risk assessment

Indexed keywords

ANTICOAGULANT AGENT; D DIMER; PHOSPHOLIPID ANTIBODY;

ARTICLE; BLEEDING; ETHNICITY; HUMAN; INFLAMMATORY BOWEL DISEASE; LUNG EMBOLISM; MALIGNANT NEOPLASTIC DISEASE; OBESITY; PREDICTION; PROTEIN DETERMINATION; RECURRENCE RISK; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; THROMBOPHILIA; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED; DECISION SUPPORT SYSTEM; DRUG ADMINISTRATION; MORTALITY; PREDICTIVE VALUE; PROCEDURES; RECURRENT DISEASE; SECONDARY PREVENTION; TIME FACTOR; TREATMENT OUTCOME;

ANTICOAGULANTS; DECISION SUPPORT TECHNIQUES; DRUG ADMINISTRATION SCHEDULE; HEMORRHAGE; HUMANS; PREDICTIVE VALUE OF TESTS; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84939796195     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S83718     Document Type: Article

References (51)

1. White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107:14–18.
2. Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000;160:761–768.
3. Christiansen SC, Cannegieter SC, Koster T, et al. Thrombophilia, clini­cal factors, and recurrent venous thrombotic events. JAMA. 2005; 293: 2352–2361.
4. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133:454S–545S.
5. Guyatt GH, Akl EA, Crowther M, et al. Executive summary: antithrom­botic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:7S–47S.
6. van Aken BE, den Heijer M, Bos GM, et al. Recurrent venous thrombosis and markers of inflammation. Thromb Haemost. 2000;83:536–539.
7. Boutitie F, Pinede L, Schulman S, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboem­bolism on risk of recurrence after stopping treatment: analysis of indi­vidual participants’ data from seven trials. BMJ. 2011;342:d3036.
8. White RH, Beyth RJ, Zhou H, et al. Major bleeding after hospitalization for deep-venous thrombosis. Am J Med. 1999;107:414–424.
9. Heit JA, Lahr BD, Petterson TM, et al. Heparin and warfarin anticoagu­lation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort study. Blood. 2011; 118:4992–4999.
10. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e419S–e494S.
11. Lip GY, Frison L, Halperin JL, et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibril­lation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011;57:173–180.
12. Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011;58:395–401.
13. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151:713–719.
14. Apostolakis S, Lane DA, Guo Y, et al. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol. 2012;60:861–867.
15. Nieto JA, Solano R, Ruiz-Ribo MD, et al. Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry. J Thromb Haemost. 2010;8:1216–1222.
16. Eichinger S, Heinze G, Jandeck LM, et al. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation. 2010;121:1630–1636.
17. Eichinger S, Heinze G, Kyrle PA. D-dimer levels over time and the risk of recurrent venous thromboembolism: an update of the Vienna prediction model. J Am Heart Assoc. 2014;3:e000467.
18. Marcucci M, Iorio A, Douketis JD, et al. Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data. J Thromb Haemost. 2015;13(5):775–781.
19. Tosetto A, Iorio A, Marcucci M, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost. 2012;10:1019–1025.
20. Rodger MA, Kahn SR, Wells PS, et al. Identifying unprovoked throm­boembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ. 2008;179:417–426.
21. Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007; 92: 199–205.
22. Galanaud JP, Sevestre MA, Genty C, et al. Incidence and predictors of venous thromboembolism recurrence after a first isolated distal deep vein thrombosis. J Thromb Haemost. 2014;12:436–443.
23. Baglin T, Douketis J, Tosetto A, et al. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. J Thromb Haemost. 2010;8:2436–2442.
24. Douketis JD, Foster GA, Crowther MA, et al. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med. 2000;160:3431–3436.
25. White RH, Murin S, Wun T, et al. Recurrent venous thromboembolism after surgery-provoked versus unprovoked thromboembolism. J Thromb Haemost. 2010;8:987–997.
26. Iorio A, Kearon C, Filippucci E, et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med. 2010;170:1710–1716.
27. Hron G, Eichinger S, Weltermann A, et al. Family history for venous throm­boembolism and the risk for recurrence. Am J Med. 2006;119:50–53.
28. Eichinger S, Hron G, Bialonczyk C, et al. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med. 2008; 168:1678–1683.
29. McRae S, Tran H, Schulman S, et al. Effect of patient’s sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet. 2006; 368:371–378.
30. Christiansen SC, Lijfering WM, Helmerhorst FM, et al. Sex difference in risk of recurrent venous thrombosis and the risk profile for a second event. J Thromb Haemost. 2010;8:2159–2168.
31. Douketis J, Tosetto A, Marcucci M, et al. Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ. 2011;342:d813.
32. Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the dura­tion of anticoagulation therapy. N Engl J Med. 2006;355:1780–1789.
33. Douketis J, Tosetto A, Marcucci M, et al. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. Ann Intern Med. 2010;153:523–531.
34. Kearon C, Spencer FA, O’Keeffe D, et al. D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop antico­agulant therapy: a cohort study. Ann Intern Med. 2015; 162: 27–34.
35. Siragusa S, Malato A, Anastasio R, et al. Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study. Blood. 2008;112:511–515.
36. Carrier M, Rodger MA, Wells PS, et al. Residual vein obstruction to predict the risk of recurrent venous thromboembolism in patients with deep vein thrombosis: a systematic review and meta-analysis. J Thromb Haemost. 2011;9:1119–1125.
37. Marchiori A, Mosena L, Prins MH, et al. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. Haematologica. 2007;92:1107–1114.
38. Cohn D, Vansenne F, de Borgie C, et al. Thrombophilia testing for prevention of recurrent venous thromboembolism. Cochrane Database Syst Rev. 2009;1:CD007069.
39. Cohn DM, Vansenne F, de Borgie CA, et al. Thrombophilia testing for prevention of recurrent venous thromboembolism. Cochrane Database Syst Rev. 2012;12:CD007069.
40. Novacek G, Weltermann A, Sobala A, et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology. 2010;139:779–787, 787. e1.
41. Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010;8:237–242.
42. White RH, Zhou H, Romano PS. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med. 1998;128:737–740.
43. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484–3488.
44. Lindhoff-Last E. Risk assessment of recurrence of venous thromboembolism. Hamostaseologie. 2011;31:7–12; quiz 13.
45. Akl EA, Barba M, Rohilla S, et al. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev. 2008;7:CD006650.
46. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboem­bolism in patients with cancer. N Engl J Med. 2003;349:146–153.
47. Louzada ML, Carrier M, Lazo-Langner A, et al. Development of a clini­cal prediction rule for risk stratification of recurrent venous thromboem­bolism in patients with cancer-associated venous thromboembolism. Circulation. 2012;126:448–454.
48. den Exter PL, Kooiman J, Huisman MV. Validation of the Ottawa prog­nostic score for the prediction of recurrent venous thromboembolism in patients with cancer-associated thrombosis. J Thromb Haemost. 2013;11:998–1000.
49. Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for pre­venting recurrent venous thromboembolism. N Engl J Med. 2012;367:1979–1987.
50. Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012;366:1959–1967.
51. Simes J, Becattini C, Agnelli G, et al. Aspirin for the prevention of recur­rent venous thromboembolism: the INSPIRE collaboration. Circulation. 2014;130(13):1062–1071.